April 19, 2018 |
LONDON, UK – April 19, 2018 – GlaxoSmithKline and Innoviva, Inc. has announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one of the biggest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.
In the study, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’ 100/62.5/25mcg) achieved superiority to members of two different classes of dual combination therapy, Relvar/Breo (FF/VI) and Anoro (UMEC/VI), on the primary endpoint of reduction in the annual rate of on-treatment moderate/severe exacerbations (p<0.001) and a range of other clinically important outcomes, including lung function and health-related quality of life.
April 16, 2018 |
WASHINGTON, D.C. – April 16, 2018 – The COPD Foundation announced today that Corinne Costa Davis has been named Interim Chief Executive Officer, effective immediately. She replaces Craig Kephart who had served in the role since May 2016. Mr. Kephart will be returning to the private sector where he previously held senior leadership positions in the specialty pharmacy arena. The COPD Foundation thanks Craig for his contributions and for continuing the legacy started by founder John Walsh in 2004.
“We are grateful to Craig for his service to the COPD Foundation. Craig stepped in following the untimely loss of John Walsh and carried us through a difficult, transitional time. We wish him well in his new endeavors” said Byron Thomashow, MD and Chairman of the Board of Directors.
The COPD Foundation welcomes Corinne Costa Davis as its new Interim Chief Executive Officer. She was elected to the COPD Foundation’s Board of Directors in 2017 and headed the Foundation’s Development Committee.
March 26, 2018 |
LONDON, UK – March 26, 2018 – Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line data from its Phase 2b study evaluating RPL554, a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 with bronchodilator and anti-inflammatory properties, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV1) at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV1 was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV1, COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD.
The four-week, double-blind, placebo-controlled, parallel group, Phase 2b multicenter European study performed in the out-patient setting evaluated the efficacy, safety, and dose-response of nebulized RPL554 administered twice-daily as a maintenance treatment for COPD in 403 patients with moderate-to-severe COPD. There were four dosing arms of RPL554 (0.75 mg, 1.5 mg, 3.0 mg and 6.0 mg) in the study in addition to placebo and patients were required to withhold use of regular long-acting bronchodilator therapy for the duration of the study.
March 07, 2018 |
WASHINGTON, D.C. – March 8, 2018 – This International Women’s Day, the COPD Foundation will host a free webinar “COPD and Women: Gender Disparities Worldwide” to address the critical impact chronic obstructive pulmonary disease (COPD) has on women and their greater communities. COPD is an umbrella term for a number of respiratory diseases such as emphysema and chronic bronchitis. The disease is characterized by an increasing inability to breathe and affects more than 200 million globally. COPD has historically been considered a “man’s disease,” however over the past 50 years COPD deaths have increased by only 27% in men versus 400% in women.
Our experts, Dr. MeiLan Han, MD, MS, is Associate Professor of Medicine in the Division of Pulmonary and Critical Care at the University of Michigan, as well as Kristen Willard and Stephanie Williams of the COPD Foundation will provide insights into the gaps in care worldwide. “If you ask a physician to envision a COPD patient, in their mind they see a man, because men are more likely to have been smokers for long periods of time," says Dr. Han.
November 03, 2017 |
NEW YORK CITY, NY – November 3, 2017 – Patient advocacy and research organization COPD Foundation paid tribute to a special group of individuals and organizations at its Annual Awards Celebration in New York City on November 2, 2017. Held at the historic Metropolitan Club, the event’s honorees were recognized for their commitment to COPD awareness and the advancement of a COPD cure. Their advocacy, research, outreach, and care-delivery efforts have helped to build a broad understanding of the disease while improving lives of those directly affected. Gerard Turino, M.D., founding chairman of the COPD Foundation, received the highest honor for his achievements in COPD research and care delivery.
“Dr. Turino is known as an innovator and thought-leader in the field of COPD research,” says Craig Kephart, Chief Executive Officer of the COPD Foundation. “His work spans many decades, pioneering the way we look at the progression and treatment of COPD today. He has been at the forefront of this effort and has played an integral part in the formation and growth of the COPD Foundation.”
October 24, 2017 |
Jvion announced a collaboration with the COPD Foundation, Geisinger, GSK to improve the lives of chronic obstructive pulmonary disease (COPD) patients. The four organizations are teaming together to help individuals with COPD stay healthier, avoid hospitalizations, and prevent readmissions following an inpatient stay.
ATLANTA, GA – October 24, 2017 – Jvion announced a unique collaboration with the COPD Foundation, Geisinger, and GSK aimed at improving the lives of chronic obstructive pulmonary disease (COPD) patients. Through an innovative approach that leverages cognitive machine technology and COPD patient data, the four organizations are teaming together in an effort to help individuals with COPD stay healthier, avoid hospitalizations, and prevent hospital readmissions following an inpatient stay. COPD encompasses a group of progressive lung diseases that gradually increase breathlessness and wheezing. The disease -- which includes emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis -- impacts more than 30 million people in the U.S. and is the nation’s third leading cause of death.
The goal of this ‘collaboratory’ project is to identify COPD patients at risk of hospitalization and most likely to benefit from new medications. The information is generated by Jvion’s Cognitive Clinical Success Machine, which identifies such patients currently under the care of Geisinger. The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace -- an approach that is a proven asset in solving complex challenges such as quantum mechanics, search and consumer behavior, facial recognition, and now patient deterioration. This Eigen-based solution enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
October 06, 2017 |
WASHINGTON, D.C. – October 6, 2017 – The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), has announced the details around its annual fundraiser. The COPD Annual Awards Celebration will be held November 2, 2017 at the Metropolitan Club in New York City from 6:30-9:30 p.m. The ceremony, hosted by COPD Foundation Board chairman Dr. Byron Thomashow, will pay tribute to individuals and organizations whose work has paved the way for COPD advocacy, research, and community building in 2017.
The Honorees are:
- John W. Walsh Visionary Award: Gerard M. Turino, M.D.
- Champion for COPD Award: Constance J. Milstein
- COPD Advocacy Award: Karen Deitemeyer
- COPD Awareness Award: FCB Health
September 29, 2017 |
WASHINGTON, D.C. – September 29, 2017 – The COPD Foundation announced today that Barbara Yawn, MD has joined the organization as Chief Scientific Officer. Dr. Yawn comes with 25 years of experience as a primary care researcher with a focus in respiratory disease, specifically asthma and chronic obstructive pulmonary disease (COPD). Additionally, she brings 14 years of full-time rural family medicine practice as well as training in research design and statistics. Dr. Yawn succeeds Dr. David Mannino in the role and will provide clinical oversight of the COPD Foundation’s overall research agenda going forward.
“Dr. Yawn is exceptionally well qualified to serve as the COPD Foundation’s chief scientific officer. She has been involved with the COPD Foundation since inception, including serving on the Foundation’s Medical and Scientific Advisory Committee (MASAC). As a primary care physician, Dr. Yawn has provided a unique and critical perspective,” says Craig Kephart, the COPD Foundation’s chief executive officer.
September 20, 2017 |
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA). Trelegy Ellipta is approved for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse.
September 19, 2017 |
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol. Trelegy Ellipta is not indicated for relief of acute bronchospasm or the treatment of asthma.
August 03, 2017 |
WASHINGTON, D.C. – August 3, 2017 – The COPD Foundation announced that four members of the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) Division of Lung Disease, Airway Biology and Disease Branch were awarded the "2017 John W. Walsh Award for Advocacy on Behalf of COPD" at its COPD10usa conference in Chicago, IL on Saturday, July 26. This inaugural award was given on behalf of the COPD Conferences (UK and USA) that are committed to recognizing individuals who have made an outstanding contribution in the field of chronic obstructive pulmonary disease (COPD). Inductees are admitted to the COPD Hall of Fame.
June 29, 2017 |
WASHINGTON, D.C./CHICAGO – June 29, 2017 – The COPD Foundation will host COPD10usa, July 28-29 2017, at Hyatt Regency O’Hare, Chicago. The event will focus on chronic obstructive pulmonary disease (COPD), the nation's third leading cause of death, providing clinical and scientific knowledge for physicians, nurses, respiratory therapists and anyone involved with the management of individuals with COPD.